All In Biotech

Drug Trial Radar · NCT06277245

A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate LNK01001 in Adults Subjects With Moderate to Severe Atopic Dermatitis.

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 356 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

356

Actual

Start

Feb 6, 2024

Primary completion

Apr 18, 2025

Study completion Jan 12, 2026

Sponsor

Lead sponsor
Lynk Pharmaceuticals Co., LtdIndustry
Sponsor type
Industry
First posted
Feb 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind study comparing LNK01001 to placebo in participants with moderately to severely atopic dermatitis who were candidates for systemic therapy (ie, patients with a history of inadequate response to topical treatments, those who were using a systemic treatment, or those for whom topical treatments are otherwise medically inadvisable). The objective of this study is to evaluate the efficacy and safety of LNK01001 in adult patients with moderate to severe AD who are candidates for systemic therapy.

Conditions

  • Atopic Dermatitis

Interventions

  • LNK01001Drug

    Capsule; Oral

  • PlaceboDrug

    Capsule; Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eczema Area and Severity Index (EASI-75) at Week 16Time frame: Baseline and Week 16
  2. Investigator's Global Assessment (IGA) score of 0/1 at Week 16Time frame: Baseline and Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatological Hospital of Southern Medical University

    Guangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.